https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u50564Fri, 28 Aug 2026 07:10:39 +0000The US FDA cleared the Elecsys pTau217 blood test, developed by Roche and Eli Lilly, to identify signs of Alzheimer's disease in adults 55 and older experiencing cognitive decline. This tool uses a single biomarker to predict the likelihood of Alzheimer's-related changes rather than providing a formal diagnosis. Labcorp and Quest Diagnostics intend to offer the test to healthcare providers.Why it mattersTraditional Alzheimer's detection often requires more invasive or expensive procedures. This blood test provides a less intrusive method for doctors to screen patients. It marks https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u49487Thu, 27 Aug 2026 04:06:19 +0000The US FDA has cleared the Elecsys pTau217 blood test developed by Roche and Eli Lilly to help detect signs of Alzheimer's disease in adults aged 55 and older with cognitive decline. The test predicts the likelihood of Alzheimer's-related changes using a single biomarker but does not provide a formal diagnosis. Labcorp and Quest Diagnostics plan to offer the test.Why it mattersThis clearance is significant for Alzheimer's diagnosis, as it provides a simpler way to assess Alzheimer's-related changes. The test is designed to aid the evaluation process for patients reporting c https://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-testhttps://www.live-feeds.com/feed/fda-clears-roche-and-eli-lilly-s-alzheimer-s-blood-test#u48407Tue, 25 Aug 2026 12:12:14 +0000The US Food and Drug Administration cleared the Elecsys pTau217 blood test developed by Roche and Eli Lilly to help detect signs of Alzheimer's disease. The test is intended for adults age 55 and older who are experiencing cognitive decline. While the test predicts the likelihood of Alzheimer's-related changes using a single biomarker, it does not provide a formal diagnosis of the brain disorder. The tool is designed to aid the evaluation process for patients reporting cognitive issues.Why it mattersTraditional Alzheimer's detection often requires more invasive or expensive proc